News Biohaven Ltd.

Equities

BHVN

VGG1110E1079

End-of-day quote Nyse Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
35.1 ^USD	-0.37%		-4.41%	-17.99%

May. 29	Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day	CI
May. 29	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day	May. 29	CI
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors	May. 29	CI
Certain Stock Options of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 18-MAY-2024.	May. 17	CI
Certain Common Shares of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 18-MAY-2024.	May. 17	CI
Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	May. 15	MT
Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing	May. 14	MT
Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates	May. 10	MT
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	Apr. 25	MT
Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO	Apr. 23	MT
Biohaven Insider Bought Shares Worth $7,999,961, According to a Recent SEC Filing	Apr. 23	MT
Biohaven Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing	Apr. 23	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Apr. 18	MT
Biohaven Prices $230 Million Public Share Offering	Apr. 18	MT
Biohaven Launches $200 Million Common Stock Offering	Apr. 17	MT
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours	Feb. 29	MT
Biohaven Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Biohaven Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Biohaven Ltd. acquired Pyramid Biosciences, Inc. for $50 million.	Feb. 28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biohaven Ltd.

Equities

BHVN

VGG1110E1079

Summary

Filters